Semaglutide Weight Management and Cardiovascular Risk Reduction
The Kansas City Cardiomyopathy Questionnaire, a patient
reported outcome, was primary endpoint in the STEP HFPEF trial
Disease
Symptoms
Symptom domains
Kansas City Cardiomyopathy Questionnaire¹
Function
limitations
Quality of
life
Functional limitation domains
Quality of life domain
Self efficacy
Stability
Symptom
frequency
Symptom
burden
Physical
limitations
Social
limitations
QoL score
Dual primary endpoint:
KCCQ clinical summary score
KCCQ score interpretation²
Health status
Score
0 to 24
Very poor to poor
Poor to fair
25 to 49
50 to 74
Fair to good
75 to 100
Good to excellent
1 Adapted from: Spertus JA. et al. JACC 2020; 76: 2379-2390; Kelkar AA et al. JACC Heart Fail 2016;4:165-175; Nassif ME et al. Circulation 2019;140:1463-1476 2. Enright PL. et al. Respir Care 2003; 48: 783-785. 2 Spertus JA, et al. JACC State-of-the-Art Review. J
Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390.
HFPEF: Heart Failure with preserved ejection fraction; KCCQ: Kansas City Cardiomyopathy QuestionnaireView entire presentation